546 related articles for article (PubMed ID: 33418929)
21. Cytokine networking of innate immunity cells: a potential target of therapy.
Striz I; Brabcova E; Kolesar L; Sekerkova A
Clin Sci (Lond); 2014 May; 126(9):593-612. PubMed ID: 24450743
[TBL] [Abstract][Full Text] [Related]
22. Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
Tsyklauri O; Chadimova T; Niederlova V; Kovarova J; Michalik J; Malatova I; Janusova S; Ivashchenko O; Rossez H; Drobek A; Vecerova H; Galati V; Kovar M; Stepanek O
Elife; 2023 Jan; 12():. PubMed ID: 36705564
[TBL] [Abstract][Full Text] [Related]
23. Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.
Qu X; Tang Y; Hua S
Front Immunol; 2018; 9():563. PubMed ID: 29662489
[TBL] [Abstract][Full Text] [Related]
24. Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E
Explor Target Antitumor Ther; 2023; 4(3):474-497. PubMed ID: 37455828
[TBL] [Abstract][Full Text] [Related]
25. Interleukin (IL)-33 and the IL-1 Family of Cytokines-Regulators of Inflammation and Tissue Homeostasis.
Vasanthakumar A; Kallies A
Cold Spring Harb Perspect Biol; 2019 Mar; 11(3):. PubMed ID: 29101106
[TBL] [Abstract][Full Text] [Related]
26. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs.
Ganea D
Adv Neuroimmunol; 1996; 6(1):61-74. PubMed ID: 8790782
[TBL] [Abstract][Full Text] [Related]
27. Cytokine regulation of natural killer cell effector functions.
Zwirner NW; Domaica CI
Biofactors; 2010; 36(4):274-88. PubMed ID: 20623510
[TBL] [Abstract][Full Text] [Related]
28. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
29. IL-36 Signaling in the Tumor Microenvironment.
Chelvanambi M; Weinstein AM; Storkus WJ
Adv Exp Med Biol; 2020; 1240():95-110. PubMed ID: 32060891
[TBL] [Abstract][Full Text] [Related]
30. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
31. Biological effects of IL-21 on immune cells and its potential for cancer treatment.
Ma M; Xie Y; Liu J; Wu L; Liu Y; Qin X
Int Immunopharmacol; 2024 Jan; 126():111154. PubMed ID: 37977064
[TBL] [Abstract][Full Text] [Related]
32. ANALYSIS OF IMMUNE CHANGES AND THEIR ROLE IN THE DEVELOPMENT OF ORAL AND OROPHARYNGEAL CANCER.
Hirna H; Kostyshyn I; Rozhko M; Levandovskyі R; Nakashidze G
Georgian Med News; 2021 Jan; (310):29-35. PubMed ID: 33658405
[TBL] [Abstract][Full Text] [Related]
33. Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.
Prezzemolo T; Guggino G; La Manna MP; Di Liberto D; Dieli F; Caccamo N
Front Immunol; 2014; 5():180. PubMed ID: 24795723
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-12 in anti-tumor immunity and immunotherapy.
Colombo MP; Trinchieri G
Cytokine Growth Factor Rev; 2002 Apr; 13(2):155-68. PubMed ID: 11900991
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles.
Seo N; Tokura Y
J Interferon Cytokine Res; 1999 Jun; 19(6):555-61. PubMed ID: 10433355
[TBL] [Abstract][Full Text] [Related]
36. Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia.
Klein B; Haggeney T; Fietz D; Indumathy S; Loveland KL; Hedger M; Kliesch S; Weidner W; Bergmann M; Schuppe HC
Hum Reprod; 2016 Oct; 31(10):2192-202. PubMed ID: 27609978
[TBL] [Abstract][Full Text] [Related]
37. Role of IL-21 in immune-regulation and tumor immunotherapy.
di Carlo E; de Totero D; Piazza T; Fabbi M; Ferrini S
Cancer Immunol Immunother; 2007 Sep; 56(9):1323-34. PubMed ID: 17447063
[TBL] [Abstract][Full Text] [Related]
38. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.
Mirlekar B
SAGE Open Med; 2022; 10():20503121211069012. PubMed ID: 35096390
[TBL] [Abstract][Full Text] [Related]
39. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
40. Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process.
Gu M; Jin Y; Gao X; Xia W; Xu T; Pan S
Front Immunol; 2023; 14():1278521. PubMed ID: 37928545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
